Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Treatment options for patients with CLL after failure of covalent BTK inhibitors and venetoclax

Krish Patel • 7 Sep 2023
SOHO 2023
Chronic Lymphocytic Leukemia Leukemia CAR-T Pirtobrutinib

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses treatment options available for patients with chronic lymphocytic leukemia (CLL) who experience disease progression following treatment with covalent BTK inhibitors and venetoclax, highlighting the potential role of BTK degraders, pirtobrutinib, and CAR-T cells. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Krish Patel

1:01
The current landscape of antibody-based therapies in R/R DLBCL
Krish Patel • 11 Dec 2023
1:31
Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel • 11 Dec 2023
1:25
Hypertension prevalence in CLL and how it is affected by acalabrutinib treatment
Krish Patel • 11 Dec 2023
1:06
Pirtobrutinib in R/R MZL: insights from the BRUIN trial
Krish Patel • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals